BackBiophytis Overview

Biophytis Total Assets

Latest total assets for BPTS: $8.7M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$8.71M
↓ 40.37% YoYΔ $-5.90M vs prior year quarter

Peer average

Loading

Biophytis Total Assets History

Loading

Biophytis vs. peers: Total Assets Comparison

Loading

Biophytis Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Biophytis (BPTS) FAQ

As of the most recent data (June 2024), BPTS shows a total assets of $8.7M. That compares with $15M in the prior-year period — down 40.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BPTS's total assets is now $8.7M (was $15M) — a 40.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Biophytis is outperforming or lagging.

Tracking BPTS's total assets over time shows whether Biophytis is scaling, shrinking, or reshaping that part of the business. The current reading is $8.7M That compares with $15M in the prior-year period — down 40.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has Biophytis's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $8.7M) with ownership activity and broader fundamentals.

Biophytis's total assets is $8.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.